共 50 条
- [41] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)CARDIOVASCULAR DIABETOLOGY, 2014, 13Zinman, BernardInzucchi, Silvio E.Lachin, John M.Wanner, ChristophFerrari, RobertoFitchett, DavidBluhmki, ErichHantel, StefanKempthorne-Rawson, JoanNewman, JenniferJohansen, Odd ErikWoerle, Hans-JuergenBroedl, Uli C.
- [42] Impact of EMPA-REG OUTCOME® on the management of type 2 diabetes mellitus: a review for primary care physiciansPOSTGRADUATE MEDICINE, 2016, 128 (08) : 822 - 827Naing, SoePoliyedath, AnupamaKhandelwal, StuteeSigala, Teresa
- [43] Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic ReviewREVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 (02) : 41 - 49Kluger, Aaron Y.Tecson, Kristen M.Barbin, Clay M.Lee, Andy Y.Lerma, Edgar, VRosol, Zachary P.Rangaswami, JananiLepor, Norman E.Cobble, Michael E.McCullough, Peter A.
- [44] Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?MOLECULAR AND CELLULAR BIOCHEMISTRY, 2017, 433 (1-2) : 97 - 102Shi, XingjuanVerma, SubodhYun, JunghwaBrand-Arzamendi, KoroboshkaSingh, Krishna K.Liu, XiangdongGarg, AnkitQuan, AdrianWen, Xiao-Yan
- [45] Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failureESC HEART FAILURE, 2020, 7 (06): : 3910 - 3918Reifsnider, Odette S.Kansal, Anuraag R.Franke, JenniferLee, JosephGeorge, Jyothis T.Brueckmann, MartinaKaspers, StefanBrand, Sarah B.Ustyugova, AnastasiaLinden, StephanStargardter, MatthewHau, Nikco
- [46] How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trialNEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (09) : 1504 - 1513Wanner, ChristophNangaku, MasaomiKraus, Bettina J.Zinman, BernardMattheus, MichaelaHantel, StefanSchumacher, MartinOhneberg, KristinSchmoor, ClaudiaInzucchi, Silvio E.
- [47] Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOMEJOURNAL OF HYPERTENSION, 2020, 38 (09) : 1829 - 1840Boehm, MichaelFitchett, DavidOfstad, Anne PernilleBrueckmann, MartinaKaspers, StefanGeorge, Jyothis T.Zwiener, IsabellaZinman, BernardWanner, ChristophMarx, NikolausMancia, GiuseppeAnker, Stefan D.Mahfoud, Felix
- [48] Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME TrialJACC-HEART FAILURE, 2021, 9 (08) : 568 - 577Sharma, AbhinavOfstad, Anne PernilleAhmad, TariqZinman, BernardZwiener, IsabellaFitchett, DavidWanner, ChristophGeorge, Jyothis T.Hantel, StefanDesai, NiharMentz, Robert J.
- [49] Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination SurveyDIABETES & VASCULAR DISEASE RESEARCH, 2020, 17 (04):Wong, Nathan D.Fan, WenjunPak, Jonathan
- [50] Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trialEUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (01) : 126 - 135Boehm, MichaelSlawik, JonathanBrueckmann, MartinaMattheus, MichaelaGeorge, Jyothis T.Ofstad, Anne PernilleInzucchi, Silvio E.Fitchett, DavidAnker, Stefan D.Marx, NikolausWanner, ChristophZinman, BernardVerma, Subodh